Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
February 27 2024 - 7:00AM
Business Wire
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
testing, today announced the next phase of proceedings in its
patent infringement litigation against CareDx. The U.S. District
Court for the District of Delaware will now determine if CareDx
owes a royalty for future infringement related to ongoing and
future AlloSure testing occurring after August 2023.
This follows a Jan. 2024 jury verdict in favor of Natera, in
which the jury awarded $96.3 million in damages to Natera in lost
profits and past royalties through August 2023. The jury found that
CareDx’s AlloSure and AlloSeq tests infringed one of the two Natera
patents asserted against CareDx and that all asserted claims of
both patents are valid on various grounds.
Discovery and briefing for this next phase are expected to last
through the end of summer 2024.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated
to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard
of care to protect health, and inform earlier, more targeted
interventions that help lead to longer, healthier lives. Natera’s
tests are validated by more than 180 peer-reviewed publications
that demonstrate high accuracy. Natera operates ISO 13485-certified
and CAP-accredited laboratories certified under the Clinical
Laboratory Improvement Amendments (CLIA) in Austin, Texas and San
Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements and
are not a representation that Natera’s plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Natera’s expectations as of the date of this press
release, and Natera disclaims any obligation to update the
forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially, including with respect to
developments in matters under dispute or litigation, the scope of
protection we establish and maintain for, and developments or
disputes concerning, our intellectual property or other proprietary
rights, and our expectations of the benefits of our tests and
product offerings to patients, providers and payers. Additional
risks and uncertainties are discussed in greater detail in “Risk
Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in
other filings Natera makes with the SEC from time to time. These
documents are available at www.natera.com/investors and
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227183728/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of
Corporate Communications, Natera, Inc., pr@natera.com
Natera (NASDAQ:NTRA)
Historical Stock Chart
From Apr 2024 to May 2024
Natera (NASDAQ:NTRA)
Historical Stock Chart
From May 2023 to May 2024